NCT03739983: Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have been receiving aromatase inhibitors (Ais) for at least 6 months prior to enrollment & plan to continue AIs for an additional 3 months

Comments are closed.

Up ↑